Patient Recruitment Case Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study for People with Large B-Cell Lymphoma

A randomized, double-blind, placebo-controlled, active-comparator, multicenter, phase 3 study of brentuximab vedotin or placebo in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

THE CLINICAL TRIAL
ECHELON-3 was initiated to determine the effectiveness of an investigational drug in treating diffuse large B-cell lymphoma (DLBCL), an aggressive form of Non-Hodgkin’s Lymphoma. Individuals living with DLBCL suffer from the accelerated development of tumors in the lymph nodes, that can spread to their spleen, liver, bone marrow, and other organs. The ECHELON-3 study examined the effectiveness of an investigational drug in combination with standard of care in the treatment of relapsed or refractory DLBCL.

THE PROJECT
For ECHELON-3, the Stark / Raving team was tasked with developing and deploying a robust recruitment toolkit aimed at assisting the Sponsor with enrollment for their study around the world. Cultivating a strong brand identity for ECHELON-3 and synthesizing a highly complex drug method of action into easily digestible language would be key to delivering a complete suite of study materials that resonated with participants and drove engagement with the study staff.

B-cell lymphoma clinical study patient recruitment branding services

Large B-cell lymphoma clinical study patient recruitment branding services

Developing a distinct brand identity for a complex disease.

Stark / Raving brought the ECHELON-3 brand to life by creating a consistent look and feel that flowed from logo design, through visual and graphical elements, and was supported by clearly written materials for this clinical study. From diverse participant imagery to thematic design elements, the brand aspects developed supported the patient’s ongoing battle against DLBCL and evoked an empowering tone that uplifted patients struggling with this debilitating form of lymphatic cancer.

Large B-cell lymphoma clinical study patient recruitment digital marketing services

Empowering patient enrollment with a broad audience reach.

To boost patient recruitment and raise awareness about the ECHELON-3 Study, Stark / Raving helped the Sponsor reach their target audience by creating print and digital banner ads promoting the study. By pairing diverse, representative imagery with optimistic and direct messaging, the Stark / Raving team created campaign materials that helped drive enrollment by emphasizing the opportunity for patients to explore a potential new treatment option being developed for DLBCL

B-cell lymphoma clinical study patient recruitment translation services

Delivering materials for global distribution.

Stark / Raving supported the global rollout of the ECHELON-3 Study by orchestrating the translation, printing, packaging, shipping, and delivery of a full suite of printed study materials in 12 languages for 16 countries and 200 global study sites.

Patient Recruitment Case Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study for People with Large B-Cell Lymphoma

A randomized, double-blind, placebo-controlled, active-comparator, multicenter, phase 3 study of brentuximab vedotin or placebo in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Developing a distinct brand identity for a complex disease.

Empowering patient enrollment with a broad audience reach.

Delivering materials for global distribution.

Put our solutions to work for your next clinical trial.